Navigation Links
Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
Date:8/1/2012

MELBOURNE, Australia, Aug. 1, 2012 /PRNewswire-Asia/ -- Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has appointed US pharmaceutical consulting company, Neura Group LLC, the consulting unit of the pain specialty company, Neura Therapeutik LLC, to provide strategic commercial and development advice for its TPM/oxycodone patch development program.

The pain specialty company, established by former Johnson & Johnson, Pfizer and King Pharmaceuticals executives in 2010, has extensive experience in the commercialisation and development of analgesics, primarily in the non-steroidal anti-inflammatory drug (NSAID) and opioid classes of the pain market.

Members of Neura's management team have launched some of the largest US analgesic brands, including the first transdermal pain patch, Duragesic® and Vicodin ES® tablets, as well as directing pain franchise build outs for pharmaceutical companies. 

The appointment will enable Phosphagenics' access to substantial development, clinical and commercial expertise in the field of pain management.

Phosphagenics CEO, Dr Esra Ogru, said the strategic partnership would assist with development, approval, partnering and marketing processes. The companies would collaborate to ensure all appropriate commercial parameters were considered in the design of the pivotal Phase 3 program.

"We remain committed and focused on the commercialisation of our TPM/oxycodone patch," Dr Ogru said.

"We are confident this partnership will ensure success at these crucial final stages. Together with our existing Pain Advisory Board, we believe the appointment of Neura will ensure the development of a commercially relevant product as we prepare a high quality package for the FDA."

Dr Ogru acknowledged Neura's ability to leverage its expertise in the analgesic market and build strong working alliances with strategic
'/>"/>

SOURCE Phosphagenics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
2. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
3. Quanterix Appoints Paul Chapman as President and Chief Executive Officer
4. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
5. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
6. C3i Appoints Jonathan Song to Business Development Executive in Asia
7. Organovo Holdings Appoints James T. Glover to Board of Directors
8. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
9. ReShape Medical Appoints Robert E. Grant to Board of Directors
10. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
11. Stereotaxis Appoints William C. Mills III as Chairman of Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and ... the addition of the "Microbiology Testing/Clinical Microbiology ... - Global Forecast to 2019" report to ... a wide array of techniques for the detection ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... ... ... , , ... PHOENIX , ...
... ... ... ... ...
Cached Medicine Technology:INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 2INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 3INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 4Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 2Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 3Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 4Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 5Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 6Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 7Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors 8
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... Step into a macabre world where plants ... Virginia. Wicked Plants, the Museum’s latest featured exhibition, opens ... carnivorous and diabolical plants inside of a dilapidated, Victorian ... biochemical, physical and neurological processes between botanicals and the ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... have come one step closer to understanding how the ... common drugs, including some antibiotics, antihistamines and anti-psychotics, can ... estimated around 40-50% of all drugs in development will ... in the heart and, as a result, can cause ...
... Maureen Salamon HealthDay Reporter , THURSDAY, Jan. 27 ... restaurant opening in his small Louisiana town, where vacant storefronts ... Burley, an assistant professor of sociology at Southeastern Louisiana University, ... of flat-screened TVs -- one in every booth -- along ...
... , THURSDAY, Jan. 27 (HealthDay News) -- U.S. health authorities ... patients using Truvada, the once-a-day combination pill that was shown ... high-risk individuals. The guidance, from experts at the U.S. ... and bisexual men at high risk for contracting the virus ...
... unprecedented crisis in our health care system," reported J. Fred ... at today,s annual State of the Nation,s Health Care briefing. ... We have more uninsured people than ever before. We ... Health care costs are increasing at rates that the countryand ...
... Researchers from McGill University,s Rosalind and Morris Goodman Cancer ... University Health Centre (RI MUHC), the DanaFarber Cancer Institute ... that can accurately predict which breast cancer patients are ... not from the burdens associated with unnecessary treatment. ...
... stimulants tend to choose instant gratification or a smaller but ... reward is greater. Reduced value of a future reward, ... treatment of addiction. A new study in the February 2011 ... present a strategy for increasing the value of future rewards ...
Cached Medicine News:Health News:Victor Chang scientists unlock the 'gates' on sudden cardiac death 2Health News:TV: A Sneaky Part of the Food Pyramid 2Health News:TV: A Sneaky Part of the Food Pyramid 3Health News:CDC Issues Guidance on Daily Pill to Prevent Infection With HIV 2Health News:CDC Issues Guidance on Daily Pill to Prevent Infection With HIV 3Health News:ACP says Congress must find 'common ground' to address 'crisis in our health care system' 2Health News:ACP says Congress must find 'common ground' to address 'crisis in our health care system' 3Health News:Memory training explored as strategy for addiction treatment 2Health News:Memory training explored as strategy for addiction treatment 3
... Counter allows the user to quickly and accurately ... for digital counting or manual counting. An optional ... increasing magnification to 3.0X. The adjustable focusing rod ... or lowered. The lens also rotates a full ...
... Darkfield Quebec Colony Counter allows the user to ... of models allows for digital counting or manual ... the standard lens increasing magnification to 3.0X. The ... to be raised or lowered. The lens also ...
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
The Accucount 1000 is designed to automatically count macroscopic objects in a field displaying totals on a highly visible digital readout....
Medicine Products: